| Quantification of the Time Course of CYP3A Inhibition, Activation, and Induction Using a Population Pharmacokinetic Model of Microdosed Midazolam Continuous Infusion YM Nassar, N Hohmann, R Michelet, K Gottwalt, AD Meid, J Burhenne, ... Clinical Pharmacokinetics 61 (11), 1595–1607, 2022 | 5 | 2022 |
| A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non‐small cell lung cancer patients FW Ojara, A Henrich, N Frances, YM Nassar, W Huisinga, N Hartung, ... CPT: Pharmacometrics & Systems Pharmacology 12 (11), 1714-1725, 2023 | 4 | 2023 |
| C-Reactive Protein as an Early Predictor of Efficacy in Advanced Non-Small-Cell Lung Cancer Patients: A Tumor Dynamics-Biomarker Modeling Framework YM Nassar, FW Ojara, A Pérez-Pitarch, K Geiger, W Huisinga, N Hartung, ... Cancers 15 (22), 5429, 2023 | 1 | 2023 |
| A joint tumour dynamics and C-reactive protein turnover model to identify early longitudinal prognostic predictors of overall survival in advanced non-small cell lung cancer … YM Nassar, FW Ojara, A Pérez Pitarch, K Geiger, W Huisinga, R Michelet, ... Population Approach Group Europe (PAGE), 2023 | | 2023 |
| Quantitative impact of different patient and disease factors on C-reactive protein (CRP) synthesis, a prognostic biomarker in advanced non-small cell lung cancer (NSCLC) patients YM Nassar, FW Ojara, A Pérez Pitarch, S Holdenrieder, K Krueger, ... 43rd European Organization of Research and Treatment of Cancer-Pharmacology …, 2022 | | 2022 |
| Cachexia-associated anticancer drug toxicity is minimally mediated by alteration of drug’s pharmacokinetics: Erlotinib as case study Y Nassar, ZP Parra-Guillén, KL Koster, W Huisinga, M Joerger, C Kloft Population Approach Group Europe (PAGE), 2022 | | 2022 |
| 112P Prognostic impact of five serum biomarkers in patients with advanced non-small cell lung cancer (NSCLC): An exploratory analysis YM Nassar, FW Ojara, S Holdenrieder, K Krueger, M Joerger, R Michelet, ... Annals of Oncology 32, S404, 2021 | | 2021 |
| Quantifying the dynamics of the modulatory effect of CYP3A perpetrators on hepatic CYP3A activity using a nonlinear mixed-effects model of microdosed midazolam and its … Y Nassar, G Mikus, W Huisinga, R Michelet, C Kloft Population Approach Group Europe (PAGE), 2021 | | 2021 |
